Project Grant HT94252410593
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$740K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
The University of Alabama at Birmingham (UAB) was awarded a $1,485,000.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to improve the oncolytic immunovirotherapy of malignant glioma by targeting the glioma secretome. The 3-year grant was awarded on September 30, 2023 and is set to conclude on September 29, 2026. UAB is a public research university known for its innovative and interdisciplinary approach to education, and it...
The University of Alabama at Birmingham (UAB) was awarded a $733,662 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, supports research to investigate the role of tumor glycans in immune suppression. This federally funded project aims to advance scientific understanding of how specific carbohydrate molecules on tumor cells can inhibit the body's immune response, with the goal of...
The University of Alabama at Birmingham (UAB) received a $1,139,184.00 Project Grant award from the Defense Health Agency for the research project "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA". The award, which began on August 15, 2023 and is scheduled for completion on August 14, 2027, is funded through the Military Medical Research and Development program (CFDA 12.420). This grant supports UAB's biomedical research efforts to transform health care for Service...
This $227,167 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research conducted by the University of Alabama at Birmingham (UAB) on macrophage-centric prognostic biomarkers for checkpoint blockade immunotherapy in melanoma. The award runs from July 1, 2025 through June 30, 2028 and aims to advance scientific understanding and treatment of this form of cancer. As a leading academic medical center, UAB has...
This $1,317,584 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by the University of Alabama at Birmingham (UAB) focused on developing prognostic biomarkers for checkpoint blockade immunotherapy in melanoma. The funding will enable UAB to conduct research spanning basic, applied, and translational investigations to transform healthcare for military service...
The University of Alabama at Birmingham will receive $742,500 through a three-year Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to uncover and target the molecular mechanisms of tumor-intrinsic immunotherapeutic resistance in melanoma. The Military Medical Research and Development program, identified by CFDA #12.420, supports basic, applied, and...
The University of Alabama at Birmingham (UAB) was awarded a $1,361,285 Phase 1/2 clinical trial grant by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a trial of the MEK inhibitor mirdametinib and TYK2 inhibitor deucravacitinib for advanced malignant peripheral nerve sheath tumors. This federally funded research project aims to advance innovative medical treatments and technologies to...
This federal Project Grant award, valued at $650,845.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports macrophage-centric prognostic biomarker research for checkpoint blockade immunotherapy in melanoma. The award, effective July 1, 2025, will fund advanced biomedical research initiatives at the University of Alabama at Birmingham (UAB) aimed at transforming healthcare for military service members and the broader...
The U.S. Defense Health Agency awarded Yale University a $912,487 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of Polycomb Repressive Complex 1 in the progression of uveal melanoma. The 3-year research project, starting on September 15, 2023 and ending on September 14, 2026, aims to advance the understanding of this specific protein complex's involvement in the development and spread of a rare form...
The University of Alabama at Birmingham will receive $519,750 through a three-year Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research on "NONCALCEMIC VITAMIN D-HYDROXY DERIVATIVES AS PREVENTIVE AND THERAPEUTIC AGENTS IN UVB-INDUCED MELANOMA" from September 1, 2022 through August 31, 2025. Through this award, researchers at the University of Alabama at Birmingham will...